PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

Efficacy of Enzalutamide (ENZ) in castration resistant prostate cancer (CRPC) patients is short-lived. Immunotherapy like T cell checkpoint blockade may improve patient survival. However, when and where checkpoint molecules are expressed in CRPC and whether immune evasion is a mechanism of ENZ resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bishop, Jennifer L., Sio, Alexander, Angeles, Arkhjamil, Roberts, Morgan E., Azad, Arun A., Chi, Kim N., Zoubeidi, Amina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381591/
https://www.ncbi.nlm.nih.gov/pubmed/25428917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381591/
https://www.ncbi.nlm.nih.gov/pubmed/25428917

Ejemplares similares